Compounded Tirzepatide in Houston
US$ 23.93
glp-1 obesity drugs pipeline Can Novo Nordisk's transform treatment? GLP-1 Agonists Weight Loss Drugs
Description
doi: 10.1016/S0140-6736(10)60406-0
The SUPRPASS-4 trial (262), involving 2002 participants with high-risk cardiovascular profiles followed for up to 104 weeks, showed no difference in 4-MACE events (cardiovascular death, myocardial infarction, stroke, and hospitalization for unstable angina) with tirzepatide compared to insulin glargine (HR 0.74
[DOI] [PMC free article] [PubMed] [Google Scholar] 487.Harndahl L., Wierup N., Enerback S., Mulder H., Manganiello V.C., Sundler F
N Engl J Med 2021;384:1719-30.ArticlePubMed 31
